Terrance P. Coyne, EVP & CFO at Royalty Pharma plc (RPRX), sold 138,540 shares at $38.67 ($5.3M) on 2025-11-24, disclosed to the SEC on 2025-11-26.
Scheduled sale ($5.3M) by EVP & CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $37.96 | 10,686 | $406K | 7.6% |
| 2 | $37.96 | 624 | $24K | 0.4% |
| 3 | $37.96 | 10,686 | $406K | 7.6% |
| 4 | $38.67 | 55,146 | $2.1M | 39.9% |
| 5 | $38.67 | 55,146 | $2.1M | 39.9% |
| 6 | $38.67 | 3,126 |
| $121K |
| 2.3% |
| 7 | $38.67 | 3,126 | $121K | 2.3% |
| Total | $38.56 avg | 138,540 | $5.3M | 100% |
| Filing → |
| RPRX | SELL | 2026-04-30 | $1.7M | — | Filing → |
| RPRX | SELL | 2026-04-02 | $1.7M | — | Filing → |
| RPRX | SELL | 2026-03-25 | $3.2M | — | Filing → |